An investigation of a novel cyclin-dependent kinase inhibitor as a treatment option for Acute Myeloid Leukaemia

Acute myeloid leukaemia (AML) is one of the most common haematological malignancies, characterised by the clonal expansion of abnormal or poorly differentiated myeloid cells, infiltrating the bone marrow (BM), blood or extramedullary tissues. Although treatment of AML has progressed over the past few decades, in some patients, particularly elderly patients, usually defined as older than 60-65 years of age, the outcome is dismal due to the remarkable genetic complexity, epigenetic alterations, and the dynamics of the disease. In this study, a newly developed CDK2/9 inhibitor CYC065 was investigated as a treatment option for AML.